Free tool
FAERS Monitor: Xpovio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212306 or its brand name (Xpovio, Selinexor). Reports on generic versions are filed under their own applications.
Reports
8,763
Serious
4,819
55% of reports
Hospitalization
2,695
Death reported
1,486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea2,648
- fatigue2,018
- decreased appetite1,406
- diarrhoea1,351
- plasma cell myeloma1,199
- vomiting956
- asthenia880
- death866
- thrombocytopenia768
- platelet count decreased698
- weight decreased654
- off label use545
- dizziness481
- pneumonia479
- anaemia469
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 12 |
| 2018 | 14 |
| 2019 | 606 |
| 2020 | 1,378 |
| 2021 | 1,439 |
| 2022 | 1,235 |
| 2023 | 1,222 |
| 2024 | 1,167 |
| 2025 | 1,051 |
| 2026 | 628 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,396 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 1,199 | 76.1 | 72.1 | 86,181 |
| thrombocytopeniaSignal | 768 | 16.6 | 15.5 | 11,219 |
| platelet count decreasedSignal | 698 | 15.8 | 14.7 | 9,658 |
| decreased appetiteSignal | 1,406 | 14.6 | 13.9 | 17,905 |
| nauseaSignal | 2,648 | 8.1 | 7.8 | 16,935 |
| fatigueSignal | 2,018 | 6.2 | 6.0 | 9,181 |
| anaemiaSignal | 469 | 5.9 | 5.4 | 1,923 |
| weight decreasedSignal | 654 | 5.6 | 5.2 | 2,516 |
| astheniaSignal | 880 | 5.6 | 5.3 | 3,397 |
| diarrhoeaSignal | 1,351 | 5.0 | 4.8 | 4,489 |
| vomitingSignal | 956 | 4.9 | 4.6 | 3,014 |
| pneumoniaSignal | 479 | 3.6 | 3.3 | 889 |
| deathSignal | 866 | 2.4 | 2.3 | 746 |
| dizzinessSignal | 481 | 2.3 | 2.1 | 367 |
| off label use | 545 | 1.5 | 1.4 | 92 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.